Description
Pantocalcin Pharmacodynamics
The spectrum of action is associated with the presence of gamma-aminobutyric acid in the structure. The mechanism of action is due to the direct effect of pantocalcin on GABA-receptor-channel complex. It has neurometabolic, neuroprotective and neurotrophic properties. Increases resistance of the brain to hypoxia and toxic substances, stimulates anabolic processes in neurons. It has anticonvulsant effect, reduces motor excitability with simultaneous ordering of behavior. Increases mental and physical performance. Contributes to normalization of gamma-aminobutyric acid during chronic alcohol intoxication and subsequent ethanol withdrawal. It shows analgesic effect. It is able to inhibit acetylation reactions participating in mechanisms of inactivation of novocaine and sulfonamides; due to this the prolongation of the latter action is achieved. It causes inhibition of pathologically increased bladder reflex and detrusor tone.
Indications
– Cognitive disorders in organic brain lesions and neurotic disorders;
– as a part of complex therapy of cerebrovascular insufficiency, caused by atherosclerotic changes in brain vessels; senile dementia (initial form), residual organic brain lesions in elderly individuals;
– cerebral organic insufficiency in patients with schizophrenia (in combination with neuroleptics, antidepressants);
– extrapyramidal hyperkinesias in patients with hereditary diseases of the nervous system (Huntington’s chorea, hepatocerebral dystrophy, Parkinson’s disease, etc.)
– consequences of neuroinfections and craniocerebral traumas (as part of the complex therapy);
– for correction of side effects of neuroleptics and with a preventive purpose simultaneously as a “cover therapy”; extrapyramidal neuroleptic syndrome (hyperkinetic and akinetic);
– epilepsy with delayed mental processes (in combination with anticonvulsants);
– psychoemotional overload, decreased mental and physical performance; for improvement of concentration and memorization;
– Urinary disorders: enuresis, daily urinary incontinence, pollakiuria, imperative urges;
– children with mental retardation (mental, speech, motor development delay or their combinations); cerebral palsy; stuttering (mainly clonic form); epilepsy (as part of combined therapy with anticonvulsants, especially for polymorphic seizures and minor epileptic seizures).
Contraindications
– Hypersensitivity;
– acute renal failure;
– Pregnancy (1st trimester).
Dosage and administration.
- Inside, 15-30 minutes after a meal.
- A single dose for adults is 0.5-1 g, for children – 0.25-0.5 g, the daily dose for adults – 1.5-3 g, for children – 0.75-3 g. Duration of treatment course is from 1 to 4 months, in some cases up to 6 months. After 3 to 6 months it is possible to carry out the second course of treatment.
- Children with mental retardation: 0.5 g 4-6 times a day, every day for 3 months, with delayed speech development – 0.5 g 3-4 times a day for 2-3 months.
- In neuroleptic syndrome (as corrector of side effects of neuroleptic agents): adults – 0.5-1 g 3 times a day, children – 0.25-0.5 g 3-4 times a day. The duration of treatment -1-3 months.
- In epilepsy: Children 0.25-0.5 g 3-4 times a day, adults – 0.5-1 g 3-4 times a day for a long time (6 months).
- In hyperkinesias (tics): children 0.25-0.5 g 3-6 times daily for 1-4 months, adults – 1.5-3 g daily for 1-5 months.
- In disorders of urination: adults 0.5-1 g 2-3 times a day (daily dose of 2-3 g), children – 0.25-0.5 g (daily dose of 25-50 mg / kg). Duration of treatment course – from 2 weeks to 3 months (depends on the severity of disorders and the therapeutic effect).
- In the aftermath of neuroinfections and craniocerebral injuries: 0.25 g 3-4 times a day.
- To restore efficiency at high loads and asthenic conditions: 0.25 g 3 times a day.
- This dosage form is not recommended for children under 3 years of age.
